Fiotec was present at the END-VOC Assembly Meeting, which brought together representatives of institutions and universities that are part of a global consortium that studies the effectiveness of vaccination against the already known variants of Covid-19 in London. From July 3rd to 5th, the meeting discussed aspects of population immunity and genomic surveillance in the countries where the research was carried out: Nigeria, India, Brazil, Mozambique, Philippines, Spain (Barcelona), Pakistan and Palestine.
According to Erica Nascimento, International Projects Analyst at Fiotec, the members of the Independent Advisory Board congratulated the consortium for the great progress achieved since last year's Assembly Meeting in Barcelona, but insisted that efforts should be redoubled in the analysis between cohorts, particularly in terms of immunity and “long Covid”: “the ability to gather data from so many different groups is the consortium's greatest strength and a way to ensure its contribution to better preparedness for pandemics in the future”, they stated at the time.
Alongside Fiocruz, Fiotec is a member of the consortium END-VOC (Ending Covid-19 Variants of Concern Through Cohort Studies). The initiative is coordinated by University College London (UCL), which hosted the second edition of the Assembly Meeting, and brings together institutions from across Europe and the countries where such studies are carried out.
